Abstract The usefulness of%[− 2] proPSA and Prostate Health Index (phi) in the detection of
prostate cancer are currently unknown. It has been suggested that these tests can …

Background: Widespread use of prostate specific antigen (PSA) in screening procedures
allowed early identification of an increasing number of prostate cancers (PCas), mainly …

BACKGROUND Total prostate-specific antigen (tPSA) is flawed for prostate cancer (PCa)
detection.[− 2] proprostate-specific antigen (p2PSA), a molecular isoform of free PSA (fPSA) …

Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …

What's known on the subject? and What does the study add? Despite the popularity of PSA
blood testing for prostate cancer, there are a number of important limitations of this popular …

Objectives To prospectively test the diagnostic accuracy of the percentage of prostate
specific antigen (PSA) isoform [–2] pro PSA (% p2 PSA) and the Prostate Health Index (PHI) …

The prostate-specific antigen (PSA) is currently the most used tumor marker in the early
detection of the prostate cancer (PCa), despite its low specificity and low negative predictive …

Study Type–Diagnostic (cost effectiveness) Level of Evidence 2b What's known on the
subject? and What does the study add? The Beckman Coulter prostate health index (phi) …

Despite its widespread use for prostate cancer screening, low specificity makes PSA a
suboptimal biomarker, especially in the diagnostic “gray zone” of 4–10 ng ml− 1. False …

Background The diagnosis of prostate cancer involves invasive, sometimes harmful,
procedures that can entail negative quality-of-life implications to individuals and high …